August 27, 2026 | Intelligent Commercialization, Pharma, healthcare
Pharma teams are under growing pressure to navigate launch complexity, identify risks earlier, and engage HCPs more effectively.

In our latest series of articles, our experts explore how Intelligent Commercialization™ is helping pharma teams turn insights into action across the lifecycle.
This content was provided by Inizio
Latest Content from Inizio
We are delighted to announce that Janssen and Research Partnership have won the BOBI (Best of Business Intelligence) Award in the Best Business Impact category at the BHBIA annual conference in London for our collaborative market research…
Growth trend continues at Pegasus with six new appointments and five promotions in the Pharma and Life Sciences team
Our client markets a product for Oral Mucositis (OM) – a side effect of cancer treatment – and wanted to better understand the disease and treatment challenges faced by both…
Our client is launching a new biologic in dermatology across indications and needed to understand the market, including the patient pool, treatment landscape, potential uptake and pricing opportunity for their…
Our client wanted to quantify how ovarian cancer patients are managed prior to product launch, but also needed to understand why patients do or do not receive key diagnostic tests…
Did you know 25% of our business is in Oncology?
In our final installment of articles exploring mental health in emerging markets, we take an in-depth look at the situation in the MENA region
Published in Pharma Exec April 2018 by Mariel Metcalfe
13-15 May, Bangkok
16-17 May in Tokyo, Japan
